Telangana Health Minister inaugurates LVPEI’s Shirin, Etian & Tara Brown Eye Centre in Hyderabad
Home care will be provided to people in and around the areas of Rajendra Nagar, Gachibowli and extending into the outskirts of the Vikarabad district
LV Prasad Eye Institute (LVPEI) has opened a new eye care centre named ‘Shirin, Etian & Tara Brown Eye Centre’ at its Gullapalli Pratibha Rao Campus in Kismatpur near Himayat Sagar. The centre was inaugurated by T Harish Rao, Minister of Finance, Health, Medical & Family Welfare, Government of Telangana. Along with the eye care centre, Rao also inaugurated LVPEI’s ‘Mobile Advanced Eye Diagnostic Unit’ dedicated to the service of rural areas of Telangana.
“We extend our sincere thanks to Harish Rao garu for joining us as the Guest of Honour, and to all our donors. We are confident that people both in urban and rural communities in Hyderabad and the state of Telangana will greatly benefit from these advanced eye care services,” says, Dr Prashant Garg, Executive Chair, LV Prasad Eye Institute.
The ‘Shirin, Etian & Tara Brown Eye Centre’ is LVPEI’s Satellite Urban Tertiary Centre in Hyderabad. The first floor of the centre has the state-of-the-art and comprehensive surgical facility. Home care will be provided to people in and around the areas of Rajendra Nagar, Gachibowli and extending into the outskirts of the Vikarabad district. Services are provided free of cost to those in need, irrespective of the complexity of care needed.
‘Pashyantu’ is LVPEI’s mobile advanced eye diagnostic unit that brings high-end eye diagnostic equipment for testing complicated eye conditions into the purview of rural secondary centres. The mobile van will visit LVPEI’s secondary eye care centres in the districts of Adilabad, Siddipet, Siricilla, Rangareddy, and Nagarkurnool periodically, making advanced eye diagnostic services accessible and affordable to the communities there right at their doorsteps.
Recommended
Dozee Shravan to remotely monitor patients
October 8, 2024
WHO adds an HPV vaccine for single-dose use
October 8, 2024